NCT02961699Unknown不适用
Healing Chronic Venous Stasis Wounds With Autologous Cell Therapy
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Time to complete wound closure as evidenced by complete epithelialization over a one-year time period (efficacy)
研究概览
简要总结
This is a prospective, randomized, single-site, safety and efficacy study of subjects with chronic venous stasis ulcers. Patients will fall into two categories: treatment arm (24 subjects) and non-treatment or control arm (12 subjects). The treatment group will undergo a small liposuction procedure and receive placement of autologous cell therapy (stromal vascular fraction or SVF) injected around the rim of venous stasis wound (subcutaneously)following standard wound debridement, with saturation of collagen dressing material with standard over-dressing. Control (non-treatment) subjects will receive debridement and dressing changes as per standard of care without SVF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18 years of age or older
- •venous leg ulcers present for at least six months and not responding to
- •standard wound therapy for at least one month prior to study treatment
- •one wound size 10-25centimeters squared
- •inpatient or outpatient treatment of chronic venous ulcers
- •the ability of subjects to give appropriate consent or have an appropriate representative available
排除标准
- •Age < 18 years of age
- •Patients who are pregnant or currently breast feeding
- •for a female subject of childbearing potential, a pregnancy test must be performed with negative results known within 7 days prior to the procedure
- •Patient with a BMI less than or equal to 18.5 or an insufficient amount of subcutaneous tissue to allow recovery of up to 100ml of lipoaspirate
- •Patients with poor glucose metabolic control (HgbA1c > 9)
- •history of local neoplasm and any history of local neoplasm and any history of local neoplasm at site of administration
- •History of systemic malignant neoplasms within last 5 years
- •Patients who require Negative Pressure Wound Therapy (NPWT) or limb amputation at the target wound at the time of screening
- •Wounds which are unable to be staged or classified. For example, full thickness tissue loss in which actual depth of the ulcer is completely obscured by slough and/or eschar in the wound bed
- •Wounds that have evidence of necrosis after debridement
- •Severe vascular disease in the pathogenesis of the ulcer (ABI<0.6)
- •Clinical signs of critical colonization or local infection
- •Prolonged(>6 months) of use of steroids
- •Patients on an active regimen of chemotherapy
- •Patients who have received radiation in proximity of the wound
- •Patients with a documented history of liver disease or an ALT value>400
- •Allergy to sodium citrate of any "caine" type of local anesthetic
- •Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. This includes completion of the Patient Reported Outcome instruments.
- •Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
- •Subject is part of a vulnerable population who, in the judgement of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, person in nursing homes, children, impoverished persons, persons in emergency situations, homeless person, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
结局指标
主要结局
Time to complete wound closure as evidenced by complete epithelialization over a one-year time period (efficacy)
时间窗: enrollment through 12 months of follow-up
time it takes for complete wound closure following procedure
Safety: as indicated through adverse event rate between control versus experimental group
时间窗: enrollment through 12 months of follow-up
adverse event rate
次要结局
- Change in wound area over time (wound healing velocity)(enrollment through 12 months of follow-up)
- assessment of disease specific quality of life (questionnaire: CIVIQ-20)(enrollment through 12 months of follow-up)
- Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life(enrollment through 12 months of follow-up)
- Percent decrease in wound size (length X width X depth)(enrollment through 12 months of follow-up)
- Assessment of overall health status (questionnaire 36-Item Short Form/SF-36)(enrollment through 12 months of follow-up)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Provant Therapy of Venous Stasis Ulcer TrialVenous Stasis UlcersNCT01050023Southern California Institute for Research and Education25
招募中
不适用
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam DressingWoundsWound of SkinWound LegVenous Leg UlcerNCT05608317Molnlycke Health Care AB20
已完成
不适用
Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac SurgeryCongenital Heart DefectsNCT02766998Boston Children's Hospital2
招募中
不适用
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas StudyChronic Kidney DiseasesEnd Stage Renal DiseaseHemodialysis Access FailureVascular Access ComplicationCatheter ComplicationsCatheter DysfunctionArteriovenous FistulaRenal FailureRenal InsufficiencyESRDNCT06001827VenoStent600
Unknown
2 期
Study of VF001-DP in Patients With Chronic Venous Leg UlcersUlcerLeg UlcerVaricose UlcerPathologic ProcessesSkin UlcerSkin DiseasesVascular DiseasesCardiovascular DiseasesNCT02973893Factor Therapeutics Ltd.156